Sanofi’s test drug to treat moderate-to-severe asthma fails to meet goalsÂ
HQ Team April 17, 2025: Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 17, 2025: Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.
US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltd’s arm — Dermavant Sciences Ltd., specialising in immuno-dermatology — for $1.2 billion.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com